PURPOSE OF REVIEW: There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the structure and function of PCSK9. RECENT FINDINGS: Therapeutic developments have not lagged far behind with some monoclonal antibodies currently entering phase III trials. Of the many approaches to PCSK9 inhibition, these compounds are the furthest advanced in their clinical development while small molecule oral inhibitors seem a distant prospect. SUMMARY: This review summarizes the discovery and history of PCSK9 and in particular its mode of action as an inhibitor of the LDL receptor. It also recapitulates key studies that have demonstrated the potential of inhibiting PCSK9 to further decrease LDL-cholesterol levels safely and synergistically with statins. Finally, we review the strategies that are currently in development to inhibit PCSK9, with a special emphasis on the spectacular results from recent phase-I and phase-II clinical trials.
PURPOSE OF REVIEW: There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the structure and function of PCSK9. RECENT FINDINGS: Therapeutic developments have not lagged far behind with some monoclonal antibodies currently entering phase III trials. Of the many approaches to PCSK9 inhibition, these compounds are the furthest advanced in their clinical development while small molecule oral inhibitors seem a distant prospect. SUMMARY: This review summarizes the discovery and history of PCSK9 and in particular its mode of action as an inhibitor of the LDL receptor. It also recapitulates key studies that have demonstrated the potential of inhibiting PCSK9 to further decrease LDL-cholesterol levels safely and synergistically with statins. Finally, we review the strategies that are currently in development to inhibit PCSK9, with a special emphasis on the spectacular results from recent phase-I and phase-II clinical trials.
Authors: Alexander V Sorokin; Zhi-Hong Yang; Boris L Vaisman; Seth Thacker; Zu-Xi Yu; Maureen Sampson; Charles N Serhan; Alan T Remaley Journal: J Nutr Biochem Date: 2016-06-19 Impact factor: 6.048
Authors: Constantine E Kosmas; Andreas Sourlas; Kyriaki V Bouza; Eddy DeJesus; Delia Silverio; Peter D Montan; Eliscer Guzman Journal: Ann Transl Med Date: 2018-04
Authors: Ji Miao; Praveen V Manthena; Mary E Haas; Alisha V Ling; Dong-Ju Shin; Mark J Graham; Rosanne M Crooke; Jingwen Liu; Sudha B Biddinger Journal: Arterioscler Thromb Vasc Biol Date: 2015-05-28 Impact factor: 8.311
Authors: Gergana Galabova; Sylvia Brunner; Gabriele Winsauer; Claudia Juno; Bettina Wanko; Andreas Mairhofer; Petra Lührs; Achim Schneeberger; Arne von Bonin; Frank Mattner; Walter Schmidt; Guenther Staffler Journal: PLoS One Date: 2014-12-04 Impact factor: 3.240
Authors: Syed Raza Shah; Mohd Faisal Uddin; Noman Lateef; Amin Muhammad Dharani; Waqas Shahnawaz; Ahmed Nabeel Kazi; Syed Arbab Shah Journal: J Community Hosp Intern Med Perspect Date: 2017-07-13
Authors: Patrick Sleiman; Jonathan Bradfield; Frank Mentch; Berta Almoguera; John Connolly; Hakon Hakonarson Journal: Front Genet Date: 2014-04-29 Impact factor: 4.599